Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Institut Paoli-Calmettes
OBJECTIVES: Primary * To assess non-relapse or progression-related mortality at 1 year in patients over 55 with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation from a matched related, filgrastim (G-CSF)-mobilized donor and treated with conditioning comprising fludarabine phosphate, busulfan, and anti-lymphocyte globulin. * To assess the incidence of graft-versus-host disease in these patients. * To assess the incidence of relapse in these patients. * To assess cellular recovery in these patients. * To assess myeloid and lymphocyte chimerism in these patients. Secondary * To study the usual clinical and biological aspects of the transplantation in these patients. * To study the impact of the Charlson score and the suitability for allogeneic transplantation score on mortality and 1-year survival. * To assess the quality of life (QLQ-C30) of these patients. * To study the economic cost of transplantation from conditioning to 1 year post-transplant. * To study the mobilization and collection of progenitor stem cells in the donors. * To study the psychological impact of donating stem cells on the donors. OUTLINE: This is a multicenter study. * Conditioning: Patients receive fludarabine phosphate IV over 30 minutes on days -5 through -1, busulphan IV over 2 hours every 6 hours on days -4 and -3, and anti-lymphocyte globulin IV over 4 hours on days -2 and -1. * Transplantation: Patients undergo allogeneic hematopoietic stem call transplantation on day 0. Patients complete a quality of life survey (QLQ-C30). After completion of study treatment, patients are followed every month for 6 months and then every 3 months for 6 months.
Age
56–74
Sex
ALL
Healthy volunteers
Not accepted
